Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did. Read how
Close

Jazz Pharmaceuticals PLC (JAZZ)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Jazz Pharma's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
109.63 -3.49    -3.09%
16:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
109.50
-0.13
-0.12%
16:17:31 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 564,155
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 109.32 - 113.72
Jazz Pharma 109.63 -3.49 -3.09%

NASDAQ:JAZZ Financials

 
A brief overview of the NASDAQ:JAZZ financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Jazz over time.

Jazz Pharmaceuticals plc reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 901.98 million compared to USD 892.81 million a year ago. Net loss was USD 14.62 million compared to net income of USD 69.42 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to basic earnings per share from continuing operations of USD 1.09 a year ago. Diluted loss per share from continuing operations was USD 0.23 compared to diluted earnings per share from continuing operations of USD 1.04 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

JAZZ Income Statement

Gross margin TTM 92.65%
Operating margin TTM 18.95%
Net Profit margin TTM 8.61%
Return on Investment TTM 6.33%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 901.98 1011.94 972.14 957.32
Gross Profit 835.44 937.04 869.99 859.78
Operating Income 105.15 234.55 172.39 157.64
Net Income -14.62 94.15 146.82 104.44

JAZZ Balance Sheet

Quick Ratio MRQ 1.62
Current Ratio MRQ 2.27
LT Debt to Equity MRQ 138.11%
Total Debt to Equity MRQ 156%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 11327.08 11393.36 11204.06 11260.54
Total Liabilities 7630.61 7656.36 7714.69 7734.86
Total Equity 3696.46 3737 3489.37 3525.68

JAZZ Cash Flow Statement

Cash Flow/Share TTM 16.66
Revenue/Share TTM 61.65
Operating Cash Flow  17.11%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 267.23 167.34 307.2 296.76
Cash From Investing Activities -271.9 101.8 -174.3 -85.74
Cash From Financing Activities -56.55 -100.31 -78.49 -96.67
Net Change in Cash -62.92 170.62 53.39 114.39
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

JAZZ Comments

Write your thoughts about Jazz Pharmaceuticals PLC
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mar 01, 2023 5:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
avadel going to destroy number 1 products sales in less than 6 months.
Reply
0 0
Report
Mar 01, 2023 5:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
do the research you'll see for yourself
Reply
0 0
Report
AL Vla
AL Vla Jul 01, 2021 11:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
FDA Approves Component of Treatment Regimen for Most Common Childhood Cancerhttps://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer
Reply
3 0
Report
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Reply
2 1
Report
Zoran Labus
Zoran Labus Mar 25, 2021 11:25AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
Reply
0 0
Report
Jesus Jerez
Jesus Jerez Feb 24, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Take into account the risks, page 44 of th eannual report: ""However, FDA confirmed that the clinical benefit of Zepzelca based on the results of the ATLANTIS Phase 3 clinical trial evaluating Zepzelca in combination with doxorubicin for relapsed SCLC did not provide sufficient verification and we and PharmaMar will therefore need to conduct one or more additional clinical trials of Zepzelca to confirm its clinical benefit. Our failure to do so could result in the withdrawal of approval of Zepzelca, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, if we are unable to comply with our post-marketing obligations imposed as part of the marketing approvals in the U.S., the EU, or other European countries, our approval may be varied, suspended or revoked, product supply may be delayed and our sales of and revenues from our products could be materially adversely affected. ""
Reply
1 0
Report
Rober Asensio
Rober Asensio Feb 15, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
PharmaMar's antiviral is 100 times more effective against Covid-19 than other treatments, reducing its viral load by almost 100%
Reply
1 1
Report
Chema Gonzalvez
Chema Gonzalvez Oct 19, 2020 11:03AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
Reply
3 2
Report
Chema Gonzalvez
Chema Gonzalvez Oct 19, 2020 11:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
Reply
4 1
Report
Miosecops cook
Miosecops cook Oct 19, 2020 11:02AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
on so ii would need samples plenty and ill make my rounds
Reply
0 0
Report
Iscritto Iscritti
Iscritto Iscritti Aug 14, 2019 8:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I see it as a very good stock and see very good income statements but don't know the company.. any downsides about it ?
Reply
1 4
Report
Wojtek Stefanowicz
Wojtek Stefanowicz Feb 20, 2019 3:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buying now
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email